Microbot Medical
MBOT
44 hedge funds and large institutions have $3.26M invested in Microbot Medical in 2025 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 19 increasing their positions, 1 reducing their positions, and 5 closing their positions.
1,800% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 1
1,641% more call options, than puts
Call options by funds: $888K | Put options by funds: $51K
163% more capital invested
Capital invested by funds: $1.24M → $3.26M (+$2.02M)
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
13% more funds holding
Funds holding: 39 → 44 (+5)
0.31% less ownership
Funds ownership: 6.52% → 6.21% (-0.31%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$498K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$308K |
| 3 |
DnB Asset Management
Oslo,
Norway
|
+$203K |
| 4 |
State Street
Boston,
Massachusetts
|
+$196K |
| 5 |
BlackRock
New York
|
+$175K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$118K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
-$11.3K |
| 3 |
DAM
Diamant Asset Management
Ridgefield,
Connecticut
|
-$11.2K |
| 4 |
JP Morgan Chase
New York
|
-$43 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$12 |
MBOT Hedge Fund Activity: Q1 2025 in Review
44 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q1 2025, worth a combined $3.26M — up 163% from $1.24M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MBOT positions and 5 closed out — a net gain of 6 holders — while 19 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, adding an estimated $498K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $118K sold.
- 44 institutional investors held Microbot Medical (MBOT) as of Q1 2025, up from 39 in Q4 2024.
- Funds reported $3.26M of Microbot Medical stock for Q1 2025, up 163% quarter-over-quarter.
- 11 funds opened new Microbot Medical positions in Q1 2025 and 5 closed out, a net change of +6 holders.
- The largest Microbot Medical buyer in Q1 2025 was Vanguard Group, an estimated $498K added.
- The largest Microbot Medical seller in Q1 2025 was Renaissance Technologies, an estimated $118K sold.
Based on aggregated 13F filings for Q1 2025.